-
1
-
-
84862796495
-
-
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm081690.htm
-
-
-
-
2
-
-
0036742053
-
Poor aqueous solubility - An industry wide problem in drug discovery
-
C. Lipinski Poor aqueous solubility - an industry wide problem in drug discovery Am. Pharm. Rev. 5 2002 82 85
-
(2002)
Am. Pharm. Rev.
, vol.5
, pp. 82-85
-
-
Lipinski, C.1
-
3
-
-
0034000453
-
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
-
H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
-
(2000)
J. Control. Release
, vol.65
, pp. 271-284
-
-
Maeda, H.1
Wu, J.2
Sawa, T.3
Matsumura, Y.4
Hori, K.5
-
4
-
-
79953048071
-
Tumor delivery of macromolecular drugs based on the EPR effect
-
V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 2011 131 135
-
(2011)
Adv. Drug Deliv. Rev.
, vol.63
, pp. 131-135
-
-
Torchilin, V.1
-
5
-
-
68549126855
-
Block copolymer micelles for delivery of cancer therapy: Transport at the whole body, tissue and cellular levels
-
A.S. Mikhail, and C. Allen Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels J. Control. Release 138 2009 214 223
-
(2009)
J. Control. Release
, vol.138
, pp. 214-223
-
-
Mikhail, A.S.1
Allen, C.2
-
7
-
-
0035858296
-
In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy
-
S.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S. Wan Kim, and M.H. Seo In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Control. Release 72 2001 191 202
-
(2001)
J. Control. Release
, vol.72
, pp. 191-202
-
-
Kim, S.C.1
Kim, D.W.2
Shim, Y.H.3
Bang, J.S.4
Oh, H.S.5
Wan Kim, S.6
Seo, M.H.7
-
8
-
-
2542559832
-
Phase i and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
-
T.Y. Kim, D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim, D.S. Heo, N.K. Kim, and Y.J. Bang Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin. Cancer Res. 10 2004 3708 3716
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 3708-3716
-
-
Kim, T.Y.1
Kim, D.W.2
Chung, J.Y.3
Shin, S.G.4
Kim, S.C.5
Heo, D.S.6
Kim, N.K.7
Bang, Y.J.8
-
9
-
-
77949526367
-
Phase i pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors
-
W.T. Lim, E.H. Tan, C.K. Toh, S.W. Hee, S.S. Leong, P.C. Ang, N.S. Wong, and B. Chowbay Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors Ann. Oncol. 21 2010 382 388
-
(2010)
Ann. Oncol.
, vol.21
, pp. 382-388
-
-
Lim, W.T.1
Tan, E.H.2
Toh, C.K.3
Hee, S.W.4
Leong, S.S.5
Ang, P.C.6
Wong, N.S.7
Chowbay, B.8
-
10
-
-
39749178252
-
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
-
K.S. Lee, H.C. Chung, S.A. Im, Y.H. Park, C.S. Kim, S.B. Kim, S.Y. Rha, M.Y. Lee, and J. Ro Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 108 2008 241 250
-
(2008)
Breast Cancer Res. Treat.
, vol.108
, pp. 241-250
-
-
Lee, K.S.1
Chung, H.C.2
Im, S.A.3
Park, Y.H.4
Kim, C.S.5
Kim, S.B.6
Rha, S.Y.7
Lee, M.Y.8
Ro, J.9
-
11
-
-
37349080672
-
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
-
D.W. Kim, S.Y. Kim, H.K. Kim, S.W. Kim, S.W. Shin, J.S. Kim, K. Park, M.Y. Lee, and D.S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Oncol. 18 2007 2009 2014
-
(2007)
Ann. Oncol.
, vol.18
, pp. 2009-2014
-
-
Kim, D.W.1
Kim, S.Y.2
Kim, H.K.3
Kim, S.W.4
Shin, S.W.5
Kim, J.S.6
Park, K.7
Lee, M.Y.8
Heo, D.S.9
-
12
-
-
42949162981
-
Multicenter phase II trial of Genexol-PM (GPM), a novel Cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (APC): Final results
-
Abstr
-
M.W. Saif, M.S. Rubin, J.A. Figueroa, and R.O. Kerr Multicenter phase II trial of Genexol-PM (GPM), a novel Cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (APC): Final results Gastrointestinal Cancers Symposium 2008 269 Abstr
-
(2008)
Gastrointestinal Cancers Symposium
, pp. 269
-
-
Saif, M.W.1
Rubin, M.S.2
Figueroa, J.A.3
Kerr, R.O.4
-
13
-
-
20944450473
-
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
-
T. Hamaguchi, Y. Matsumura, M. Suzuki, K. Shimizu, R. Goda, I. Nakamura, I. Nakatomi, M. Yokoyama, K. Kataoka, and T. Kakizoe NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 92 2005 1240 1246
-
(2005)
Br. J. Cancer
, vol.92
, pp. 1240-1246
-
-
Hamaguchi, T.1
Matsumura, Y.2
Suzuki, M.3
Shimizu, K.4
Goda, R.5
Nakamura, I.6
Nakatomi, I.7
Yokoyama, M.8
Kataoka, K.9
Kakizoe, T.10
-
14
-
-
33748289523
-
NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
-
T. Negishi, F. Koizumi, H. Uchino, J. Kuroda, T. Kawaguchi, S. Naito, and Y. Matsumura NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel Br. J. Cancer 95 2006 601 606
-
(2006)
Br. J. Cancer
, vol.95
, pp. 601-606
-
-
Negishi, T.1
Koizumi, F.2
Uchino, H.3
Kuroda, J.4
Kawaguchi, T.5
Naito, S.6
Matsumura, Y.7
-
15
-
-
34447331464
-
A phase i and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
-
T. Hamaguchi, K. Kato, H. Yasui, C. Morizane, M. Ikeda, H. Ueno, K. Muro, Y. Yamada, T. Okusaka, K. Shirao, Y. Shimada, H. Nakahama, and Y. Matsumura A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation Br. J. Cancer 97 2007 170 176
-
(2007)
Br. J. Cancer
, vol.97
, pp. 170-176
-
-
Hamaguchi, T.1
Kato, K.2
Yasui, H.3
Morizane, C.4
Ikeda, M.5
Ueno, H.6
Muro, K.7
Yamada, Y.8
Okusaka, T.9
Shirao, K.10
Shimada, Y.11
Nakahama, H.12
Matsumura, Y.13
-
16
-
-
0346059586
-
Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice
-
N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, and K. Kataoka Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 63 2003 8977 8983
-
(2003)
Cancer Res.
, vol.63
, pp. 8977-8983
-
-
Nishiyama, N.1
Okazaki, S.2
Cabral, H.3
Miyamoto, M.4
Kato, Y.5
Sugiyama, Y.6
Nishio, K.7
Matsumura, Y.8
Kataoka, K.9
-
17
-
-
27144472720
-
Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
-
H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. Nishiyama, K. Kataoka, S. Naito, and T. Kakizoe Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 93 2005 678 687
-
(2005)
Br. J. Cancer
, vol.93
, pp. 678-687
-
-
Uchino, H.1
Matsumura, Y.2
Negishi, T.3
Koizumi, F.4
Hayashi, T.5
Honda, T.6
Nishiyama, N.7
Kataoka, K.8
Naito, S.9
Kakizoe, T.10
-
18
-
-
79951682119
-
A Phase i clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
-
R. Plummer, R.H. Wilson, H. Calvert, A.V. Boddy, M. Griffin, J. Sludden, M.J. Tilby, M. Eatock, D.G. Pearson, C.J. Ottley, Y. Matsumura, K. Kataoka, and T. Nishiya A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Br. J. Cancer 104 2011 593 598
-
(2011)
Br. J. Cancer
, vol.104
, pp. 593-598
-
-
Plummer, R.1
Wilson, R.H.2
Calvert, H.3
Boddy, A.V.4
Griffin, M.5
Sludden, J.6
Tilby, M.J.7
Eatock, M.8
Pearson, D.G.9
Ottley, C.J.10
Matsumura, Y.11
Kataoka, K.12
Nishiya, T.13
-
19
-
-
84862825627
-
-
http://www.nanocarrier.co.jp/en/research/pipeline/03.html
-
-
-
-
20
-
-
33750549679
-
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors
-
F. Koizumi, M. Kitagawa, T. Negishi, T. Onda, S. Matsumoto, T. Hamaguchi, and Y. Matsumura Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors Cancer Res. 66 2006 10048 10056
-
(2006)
Cancer Res.
, vol.66
, pp. 10048-10056
-
-
Koizumi, F.1
Kitagawa, M.2
Negishi, T.3
Onda, T.4
Matsumoto, S.5
Hamaguchi, T.6
Matsumura, Y.7
-
21
-
-
77958073029
-
Phase i study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors
-
T. Hamaguchi, T. Doi, T. Eguchi-Nakajima, K. Kato, Y. Yamada, Y. Shimada, N. Fuse, A. Ohtsu, S. Matsumoto, M. Takanashi, and Y. Matsumura Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors Clin. Cancer Res. 16 2010 5058 5066
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 5058-5066
-
-
Hamaguchi, T.1
Doi, T.2
Eguchi-Nakajima, T.3
Kato, K.4
Yamada, Y.5
Shimada, Y.6
Fuse, N.7
Ohtsu, A.8
Matsumoto, S.9
Takanashi, M.10
Matsumura, Y.11
-
22
-
-
0035816145
-
Development of the polymer micelle carrier system for doxorubicin
-
T. Nakanishi, S. Fukushima, K. Okamoto, M. Suzuki, Y. Matsumura, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Development of the polymer micelle carrier system for doxorubicin J. Control. Release 74 2001 295 302
-
(2001)
J. Control. Release
, vol.74
, pp. 295-302
-
-
Nakanishi, T.1
Fukushima, S.2
Okamoto, K.3
Suzuki, M.4
Matsumura, Y.5
Yokoyama, M.6
Okano, T.7
Sakurai, Y.8
Kataoka, K.9
-
23
-
-
10844293438
-
Phase i clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
-
Y. Matsumura, T. Hamaguchi, T. Ura, K. Muro, Y. Yamada, Y. Shimada, K. Shirao, T. Okusaka, H. Ueno, M. Ikeda, and N. Watanabe Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 91 2004 1775 1781
-
(2004)
Br. J. Cancer
, vol.91
, pp. 1775-1781
-
-
Matsumura, Y.1
Hamaguchi, T.2
Ura, T.3
Muro, K.4
Yamada, Y.5
Shimada, Y.6
Shirao, K.7
Okusaka, T.8
Ueno, H.9
Ikeda, M.10
Watanabe, N.11
-
24
-
-
0032867434
-
Block copolymer-based formulation of doxorubicin. from cell screen to clinical trials
-
V. Alakhov, E. Klinski, S. Li, G. Pietrzynski, A. Venne, E. Batrakova, T. Bronitch, and A. Kabanov Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials Colloids Surf., B 16 1999 113 134
-
(1999)
Colloids Surf., B
, vol.16
, pp. 113-134
-
-
Alakhov, V.1
Klinski, E.2
Li, S.3
Pietrzynski, G.4
Venne, A.5
Batrakova, E.6
Bronitch, T.7
Kabanov, A.8
-
25
-
-
1942470679
-
Phase i dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
-
S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, D. Jowle, M. Brampton, G. Halbert, and M. Ranson Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer Br. J. Cancer 90 2004 2085 2091
-
(2004)
Br. J. Cancer
, vol.90
, pp. 2085-2091
-
-
Danson, S.1
Ferry, D.2
Alakhov, V.3
Margison, J.4
Kerr, D.5
Jowle, D.6
Brampton, M.7
Halbert, G.8
Ranson, M.9
-
26
-
-
84855921796
-
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
-
J. Valle, A. Armstrong, C. Newman, V. Alakhov, G. Pietrzynski, J. Brewer, S. Campbell, P. Corrie, E. Rowinsky, and M. Ranson A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction Invest. New Drugs 29 2010 1029 1037
-
(2010)
Invest. New Drugs
, vol.29
, pp. 1029-1037
-
-
Valle, J.1
Armstrong, A.2
Newman, C.3
Alakhov, V.4
Pietrzynski, G.5
Brewer, J.6
Campbell, S.7
Corrie, P.8
Rowinsky, E.9
Ranson, M.10
-
27
-
-
0027968083
-
A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer
-
C.M. Spencer, D. Faulds, and Paclitaxel A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer Drugs 48 1994 794 847
-
(1994)
Drugs
, vol.48
, pp. 794-847
-
-
Spencer, C.M.1
Faulds, D.2
Paclitaxel3
-
28
-
-
0034880214
-
Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation
-
H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
-
(2001)
Eur. J. Cancer
, vol.37
, pp. 1590-1598
-
-
Gelderblom, H.1
Verweij, J.2
Nooter, K.3
Sparreboom, A.4
-
29
-
-
0037413394
-
An alternative paclitaxel microemulsion formulation: Hypersensitivity evaluation and pharmacokinetic profile
-
L. He, G.L. Wang, and Q. Zhang An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile Int. J. Pharm. 250 2003 45 50
-
(2003)
Int. J. Pharm.
, vol.250
, pp. 45-50
-
-
He, L.1
Wang, G.L.2
Zhang, Q.3
-
30
-
-
77954534436
-
Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery
-
R.R. Sawant, O.S. Vaze, K. Rockwell, and V.P. Torchilin Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery Eur. J. Pharm. Biopharm. 75 2010 321 326
-
(2010)
Eur. J. Pharm. Biopharm.
, vol.75
, pp. 321-326
-
-
Sawant, R.R.1
Vaze, O.S.2
Rockwell, K.3
Torchilin, V.P.4
-
31
-
-
33746222883
-
Development of first photoresponsive prodrug of paclitaxel
-
M. Skwarczynski, M. Noguchi, S. Hirota, Y. Sohma, T. Kimura, Y. Hayashi, and Y. Kiso Development of first photoresponsive prodrug of paclitaxel Bioorg. Med. Chem. Lett. 16 2006 4492 4496
-
(2006)
Bioorg. Med. Chem. Lett.
, vol.16
, pp. 4492-4496
-
-
Skwarczynski, M.1
Noguchi, M.2
Hirota, S.3
Sohma, Y.4
Kimura, T.5
Hayashi, Y.6
Kiso, Y.7
-
32
-
-
80052184165
-
Novel paclitaxel nanoparticles: Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation
-
G.V. Shavi, A.R. Kumar, A. Karthik, M. Naseer, G. Aravind, B.D. Praful, M.S. Reddy, and N. Udupa Novel paclitaxel nanoparticles: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation J. Control. Release 148 2010 e119 e121
-
(2010)
J. Control. Release
, vol.148
-
-
Shavi, G.V.1
Kumar, A.R.2
Karthik, A.3
Naseer, M.4
Aravind, G.5
Praful, B.D.6
Reddy, M.S.7
Udupa, N.8
-
33
-
-
67349143352
-
Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles
-
J. Gong, M. Huo, J. Zhou, Y. Zhang, X. Peng, D. Yu, H. Zhang, and J. Li Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles Int. J. Pharm. 376 2009 161 168
-
(2009)
Int. J. Pharm.
, vol.376
, pp. 161-168
-
-
Gong, J.1
Huo, M.2
Zhou, J.3
Zhang, Y.4
Peng, X.5
Yu, D.6
Zhang, H.7
Li, J.8
-
34
-
-
20344370984
-
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)
-
A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals, W.D. Figg, M. Hawkins, and N. Desai Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 4136-4143
-
-
Sparreboom, A.1
Scripture, C.D.2
Trieu, V.3
Williams, P.J.4
De, T.5
Yang, A.6
Beals, B.7
Figg, W.D.8
Hawkins, M.9
Desai, N.10
-
35
-
-
0029980834
-
Development of amphiphilic diblock copolymers as micellar carriers of taxol
-
X. Zhang, J.K. Jackson, and H.M. Burt Development of amphiphilic diblock copolymers as micellar carriers of taxol Int. J. Pharm. 132 1996 195 206
-
(1996)
Int. J. Pharm.
, vol.132
, pp. 195-206
-
-
Zhang, X.1
Jackson, J.K.2
Burt, H.M.3
-
36
-
-
0032828963
-
Development of copolymers of poly(D, L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel
-
H.M. Burt, X. Zhang, P. Toleikis, L. Embree, and W.L. Hunter Development of copolymers of poly(D, L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel Colloids Surf., B 16 1999 161 171
-
(1999)
Colloids Surf., B
, vol.16
, pp. 161-171
-
-
Burt, H.M.1
Zhang, X.2
Toleikis, P.3
Embree, L.4
Hunter, W.L.5
-
37
-
-
0030965632
-
An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel
-
X. Zhang, H.M. Burt, D. Von Hoff, D. Dexter, G. Mangold, D. Degen, A.M. Oktaba, and W.L. Hunter An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel Cancer Chemother. Pharmacol. 40 1997 81 86
-
(1997)
Cancer Chemother. Pharmacol.
, vol.40
, pp. 81-86
-
-
Zhang, X.1
Burt, H.M.2
Von Hoff, D.3
Dexter, D.4
Mangold, G.5
Degen, D.6
Oktaba, A.M.7
Hunter, W.L.8
-
38
-
-
44649136172
-
Fast Release of Lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo förster resonance energy transfer imaging
-
H. Chen, S. Kim, W. He, H. Wang, P.S. Low, K. Park, and J.-X. Cheng Fast Release of Lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo förster resonance energy transfer imaging Langmuir 24 2008 5213 5217
-
(2008)
Langmuir
, vol.24
, pp. 5213-5217
-
-
Chen, H.1
Kim, S.2
He, W.3
Wang, H.4
Low, P.S.5
Park, K.6
Cheng, J.-X.7
-
39
-
-
0030827821
-
Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
-
X. Zhang, H.M. Burt, G. Mangold, D. Dexter, D. Von Hoff, L. Mayer, and W.L. Hunter Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel Anticancer Drugs 8 1997 696 701
-
(1997)
Anticancer Drugs
, vol.8
, pp. 696-701
-
-
Zhang, X.1
Burt, H.M.2
Mangold, G.3
Dexter, D.4
Von Hoff, D.5
Mayer, L.6
Hunter, W.L.7
-
40
-
-
0031872770
-
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
-
A. Sparreboom, J. Verweij, M.E. van der Burg, W.J. Loos, E. Brouwer, L. Vigano, A. Locatelli, A.I. de Vos, K. Nooter, G. Stoter, and L. Gianni Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo Clin. Cancer Res. 4 1998 1937 1942
-
(1998)
Clin. Cancer Res.
, vol.4
, pp. 1937-1942
-
-
Sparreboom, A.1
Verweij, J.2
Van Der Burg, M.E.3
Loos, W.J.4
Brouwer, E.5
Vigano, L.6
Locatelli, A.7
De Vos, A.I.8
Nooter, K.9
Stoter, G.10
Gianni, L.11
-
41
-
-
0036096946
-
Phase i and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
-
N.K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R.L. Theriault, E. Rivera, B. Esmaeli, S.E. Ring, A. Bedikian, G.N. Hortobagyi, and J.A. Ellerhorst Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin. Cancer Res. 8 2002 1038 1044
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 1038-1044
-
-
Ibrahim, N.K.1
Desai, N.2
Legha, S.3
Soon-Shiong, P.4
Theriault, R.L.5
Rivera, E.6
Esmaeli, B.7
Ring, S.E.8
Bedikian, A.9
Hortobagyi, G.N.10
Ellerhorst, J.A.11
-
42
-
-
24944505659
-
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
-
N.K. Ibrahim, B. Samuels, R. Page, D. Doval, K.M. Patel, S.C. Rao, M.K. Nair, P. Bhar, N. Desai, and G.N. Hortobagyi Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J. Clin. Oncol. 23 2005 6019 6026
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 6019-6026
-
-
Ibrahim, N.K.1
Samuels, B.2
Page, R.3
Doval, D.4
Patel, K.M.5
Rao, S.C.6
Nair, M.K.7
Bhar, P.8
Desai, N.9
Hortobagyi, G.N.10
-
43
-
-
32944482677
-
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
-
W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 2005 7794 7803
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 7794-7803
-
-
Gradishar, W.J.1
Tjulandin, S.2
Davidson, N.3
Shaw, H.4
Desai, N.5
Bhar, P.6
Hawkins, M.7
O'Shaughnessy, J.8
-
44
-
-
33747887418
-
Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
-
M.R. Green, G.M. Manikhas, S. Orlov, B. Afanasyev, A.M. Makhson, P. Bhar, and M.J. Hawkins Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann. Oncol. 17 2006 1263 1268
-
(2006)
Ann. Oncol.
, vol.17
, pp. 1263-1268
-
-
Green, M.R.1
Manikhas, G.M.2
Orlov, S.3
Afanasyev, B.4
Makhson, A.M.5
Bhar, P.6
Hawkins, M.J.7
-
45
-
-
0034306321
-
Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
-
U. Gatzemeier, J. von Pawel, M. Gottfried, G.P. ten Velde, K. Mattson, F. de Marinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, J. Bogaerts, and G. Gallant Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 18 2000 3390 3399
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 3390-3399
-
-
Gatzemeier, U.1
Von Pawel, J.2
Gottfried, M.3
Ten Velde, G.P.4
Mattson, K.5
De Marinis, F.6
Harper, P.7
Salvati, F.8
Robinet, G.9
Lucenti, A.10
Bogaerts, J.11
Gallant, G.12
-
46
-
-
0036167369
-
Biological basis for chemo-radiotherapy interactions
-
C. Hennequin, and V. Favaudon Biological basis for chemo-radiotherapy interactions Eur. J. Cancer 38 2002 223 230
-
(2002)
Eur. J. Cancer
, vol.38
, pp. 223-230
-
-
Hennequin, C.1
Favaudon, V.2
-
47
-
-
84864053366
-
Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: A phase III study
-
doi:10.1007/s12032-010-9811-x doi
-
A.A. Halim, H.A. Wahba, H.A. El-Hadaad, and A. Abo-Elyazeed Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study Med. Oncol. 2011 doi: 10.1007/s12032-010-9811-x
-
(2011)
Med. Oncol.
-
-
Halim, A.A.1
Wahba, H.A.2
El-Hadaad, H.A.3
Abo-Elyazeed, A.4
-
48
-
-
84862788431
-
A Phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer
-
W.C. Chen, J. Kim, E. Kim, P. Silverman, B. Overmoyer, B.W. Cooper, S. Anthony, R. Shenk, R. Leeming, S.H. Hanks, and J.A. Lyons A Phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer Int. J. Radiat. Oncol. 2010 1 7
-
(2010)
Int. J. Radiat. Oncol.
, pp. 1-7
-
-
Chen, W.C.1
Kim, J.2
Kim, E.3
Silverman, P.4
Overmoyer, B.5
Cooper, B.W.6
Anthony, S.7
Shenk, R.8
Leeming, R.9
Hanks, S.H.10
Lyons, J.A.11
-
49
-
-
84862825628
-
-
http://www.nanocarrier.co.jp/en/company/history.html
-
-
-
-
52
-
-
0032803387
-
Preparation and Characterization of self-assembled polymer-metal complex micelle from cis-Dichlorodiammineplatinum(II) and Poly(ethylene glycol)-Poly(α, β-aspartic acid) block copolymer in an aqueous medium
-
N. Nishiyama, M. Yokoyama, T. Aoyagi, T. Okano, Y. Sakurai, and K. Kataoka Preparation and Characterization of self-assembled polymer-metal complex micelle from cis-Dichlorodiammineplatinum(II) and Poly(ethylene glycol)-Poly(α, β-aspartic acid) block copolymer in an aqueous medium Langmuir 15 1998 377 383
-
(1998)
Langmuir
, vol.15
, pp. 377-383
-
-
Nishiyama, N.1
Yokoyama, M.2
Aoyagi, T.3
Okano, T.4
Sakurai, Y.5
Kataoka, K.6
-
53
-
-
0037344002
-
Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles
-
N. Nishiyama, F. Koizumi, S. Okazaki, Y. Matsumura, K. Nishio, and K. Kataoka Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles Bioconjug. Chem. 14 2003 449 457
-
(2003)
Bioconjug. Chem.
, vol.14
, pp. 449-457
-
-
Nishiyama, N.1
Koizumi, F.2
Okazaki, S.3
Matsumura, Y.4
Nishio, K.5
Kataoka, K.6
-
54
-
-
0034867065
-
Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system
-
N. Nishiyama, Y. Kato, Y. Sugiyama, and K. Kataoka Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system Pharm. Res. 18 2001 1035 1041
-
(2001)
Pharm. Res.
, vol.18
, pp. 1035-1041
-
-
Nishiyama, N.1
Kato, Y.2
Sugiyama, Y.3
Kataoka, K.4
-
55
-
-
84962710843
-
NC-6004, a novel cisplatin-incorporated polymeric micelle, is highly effective against oxaliplatin-resistant tumor models
-
Abstr
-
N. Alami, K. Banerjee, S. Juste, V. Page, M. Brossard, T. Hayashi, E. Igarashi, and B.L. Jones NC-6004, a novel cisplatin-incorporated polymeric micelle, is highly effective against oxaliplatin-resistant tumor models Proc. Am. Assoc. Cancer Res. 47 2006 562 Abstr
-
(2006)
Proc. Am. Assoc. Cancer Res.
, vol.47
, pp. 562
-
-
Alami, N.1
Banerjee, K.2
Juste, S.3
Page, V.4
Brossard, M.5
Hayashi, T.6
Igarashi, E.7
Jones, B.L.8
-
56
-
-
84862796491
-
-
http://www.nanocarrier.co.jp/en/news/topics/pdf/e20101013.pdf
-
-
-
-
57
-
-
10044271109
-
Preparation and biological properties of dichloro(1,2-diaminocyclohexane) platinum(II) (DACHPt)-loaded polymeric micelles
-
H. Cabral, N. Nishiyama, S. Okazaki, H. Koyama, and K. Kataoka Preparation and biological properties of dichloro(1,2-diaminocyclohexane) platinum(II) (DACHPt)-loaded polymeric micelles J. Control. Release 101 2005 223 232
-
(2005)
J. Control. Release
, vol.101
, pp. 223-232
-
-
Cabral, H.1
Nishiyama, N.2
Okazaki, S.3
Koyama, H.4
Kataoka, K.5
-
58
-
-
34547673162
-
Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity
-
H. Cabral, N. Nishiyama, and K. Kataoka Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity J. Control. Release 121 2007 146 155
-
(2007)
J. Control. Release
, vol.121
, pp. 146-155
-
-
Cabral, H.1
Nishiyama, N.2
Kataoka, K.3
-
59
-
-
40949135609
-
Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression
-
M. Sumitomo, F. Koizumi, T. Asano, A. Horiguchi, K. Ito, T. Kakizoe, M. Hayakawa, and Y. Matsumura Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression Cancer Res. 68 2008 1631 1635
-
(2008)
Cancer Res.
, vol.68
, pp. 1631-1635
-
-
Sumitomo, M.1
Koizumi, F.2
Asano, T.3
Horiguchi, A.4
Ito, K.5
Kakizoe, T.6
Hayakawa, M.7
Matsumura, Y.8
-
60
-
-
43549107330
-
Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor
-
Y. Saito, M. Yasunaga, J. Kuroda, Y. Koga, and Y. Matsumura Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor Cancer Sci. 99 2008 1258 1264
-
(2008)
Cancer Sci.
, vol.99
, pp. 1258-1264
-
-
Saito, Y.1
Yasunaga, M.2
Kuroda, J.3
Koga, Y.4
Matsumura, Y.5
-
61
-
-
64249091937
-
Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma
-
J. Kuroda, J. Kuratsu, M. Yasunaga, Y. Koga, Y. Saito, and Y. Matsumura Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma Int. J. Cancer 124 2009 2505 2511
-
(2009)
Int. J. Cancer
, vol.124
, pp. 2505-2511
-
-
Kuroda, J.1
Kuratsu, J.2
Yasunaga, M.3
Koga, Y.4
Saito, Y.5
Matsumura, Y.6
-
62
-
-
77957599889
-
The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts
-
H. Kenmotsu, M. Yasunaga, K. Goto, T. Nagano, J. Kuroda, Y. Koga, A. Takahashi, Y. Nishiwaki, and Y. Matsumura The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts Cancer 116 2010 4597 4604
-
(2010)
Cancer
, vol.116
, pp. 4597-4604
-
-
Kenmotsu, H.1
Yasunaga, M.2
Goto, K.3
Nagano, T.4
Kuroda, J.5
Koga, Y.6
Takahashi, A.7
Nishiwaki, Y.8
Matsumura, Y.9
-
63
-
-
75149138953
-
Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour
-
Y. Saito, M. Yasunaga, J. Kuroda, Y. Koga, and Y. Matsumura Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour Eur. J. Cancer 46 2010 650 658
-
(2010)
Eur. J. Cancer
, vol.46
, pp. 650-658
-
-
Saito, Y.1
Yasunaga, M.2
Kuroda, J.3
Koga, Y.4
Matsumura, Y.5
-
64
-
-
78049492128
-
Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer
-
T. Nagano, M. Yasunaga, K. Goto, H. Kenmotsu, Y. Koga, J. Kuroda, Y. Nishimura, T. Sugino, Y. Nishiwaki, and Y. Matsumura Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer Int. J. Cancer 127 2010 2699 2706
-
(2010)
Int. J. Cancer
, vol.127
, pp. 2699-2706
-
-
Nagano, T.1
Yasunaga, M.2
Goto, K.3
Kenmotsu, H.4
Koga, Y.5
Kuroda, J.6
Nishimura, Y.7
Sugino, T.8
Nishiwaki, Y.9
Matsumura, Y.10
-
65
-
-
67650360798
-
Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment
-
T. Nagano, M. Yasunaga, K. Goto, H. Kenmotsu, Y. Koga, J. Kuroda, Y. Nishimura, T. Sugino, Y. Nishiwaki, and Y. Matsumura Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment Clin. Cancer Res. 15 2009 4348 4355
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 4348-4355
-
-
Nagano, T.1
Yasunaga, M.2
Goto, K.3
Kenmotsu, H.4
Koga, Y.5
Kuroda, J.6
Nishimura, Y.7
Sugino, T.8
Nishiwaki, Y.9
Matsumura, Y.10
-
66
-
-
77957592476
-
Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases
-
A. Takahashi, N. Ohkohchi, M. Yasunaga, J. Kuroda, Y. Koga, H. Kenmotsu, T. Kinoshita, and Y. Matsumura Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases Clin. Cancer Res. 16 2010 4822 4831
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 4822-4831
-
-
Takahashi, A.1
Ohkohchi, N.2
Yasunaga, M.3
Kuroda, J.4
Koga, Y.5
Kenmotsu, H.6
Kinoshita, T.7
Matsumura, Y.8
-
67
-
-
40749107087
-
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil
-
T.E. Nakajima, M. Yasunaga, Y. Kano, F. Koizumi, K. Kato, T. Hamaguchi, Y. Yamada, K. Shirao, Y. Shimada, and Y. Matsumura Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil Int. J. Cancer 122 2008 2148 2153
-
(2008)
Int. J. Cancer
, vol.122
, pp. 2148-2153
-
-
Nakajima, T.E.1
Yasunaga, M.2
Kano, Y.3
Koizumi, F.4
Kato, K.5
Hamaguchi, T.6
Yamada, Y.7
Shirao, K.8
Shimada, Y.9
Matsumura, Y.10
-
68
-
-
56449127975
-
Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan
-
T.E. Nakajima, K. Yanagihara, M. Takigahira, M. Yasunaga, K. Kato, T. Hamaguchi, Y. Yamada, Y. Shimada, K. Mihara, T. Ochiya, and Y. Matsumura Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan Cancer Res. 68 2008 9318 9322
-
(2008)
Cancer Res.
, vol.68
, pp. 9318-9322
-
-
Nakajima, T.E.1
Yanagihara, K.2
Takigahira, M.3
Yasunaga, M.4
Kato, K.5
Hamaguchi, T.6
Yamada, Y.7
Shimada, Y.8
Mihara, K.9
Ochiya, T.10
Matsumura, Y.11
-
69
-
-
59149087789
-
A phase i dose-escalation study of NK012
-
Abstr
-
H.A. Burris, J.R. Infante, D.R. Spigel, F.A. Greco, D.S. Thompson, S. Matsumoto, S. Kawamura, and S.F. Jones A phase I dose-escalation study of NK012 J. Clin. Oncol. 26 2008 2538 Abstr
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 2538
-
-
Burris, H.A.1
Infante, J.R.2
Spigel, D.R.3
Greco, F.A.4
Thompson, D.S.5
Matsumoto, S.6
Kawamura, S.7
Jones, S.F.8
-
70
-
-
0034047312
-
Phase i dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
-
H.C. Pitot, R.M. Goldberg, J.M. Reid, J.A. Sloan, P.A. Skaff, C. Erlichman, J. Rubin, P.A. Burch, A.A. Adjei, S.A. Alberts, L.J. Schaaf, G. Elfring, and L.L. Miller Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy Clin. Cancer Res. 6 2000 2236 2244
-
(2000)
Clin. Cancer Res.
, vol.6
, pp. 2236-2244
-
-
Pitot, H.C.1
Goldberg, R.M.2
Reid, J.M.3
Sloan, J.A.4
Skaff, P.A.5
Erlichman, C.6
Rubin, J.7
Burch, P.A.8
Adjei, A.A.9
Alberts, S.A.10
Schaaf, L.J.11
Elfring, G.12
Miller, L.L.13
-
71
-
-
0028853410
-
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase i trials
-
G.G. Chabot, D. Abigerges, G. Catimel, S. Culine, M. de Forni, J.M. Extra, M. Mahjoubi, P. Herait, J.P. Armand, and R. Bugat Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials Ann. Oncol. 6 1995 141 151
-
(1995)
Ann. Oncol.
, vol.6
, pp. 141-151
-
-
Chabot, G.G.1
Abigerges, D.2
Catimel, G.3
Culine, S.4
De Forni, M.5
Extra, J.M.6
Mahjoubi, M.7
Herait, P.8
Armand, J.P.9
Bugat, R.10
-
72
-
-
84862831872
-
-
http://clinicaltrialsfeeds.org/clinical-trials/results/term=nk012
-
-
-
-
73
-
-
0000428523
-
Preparation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. A new type of polymeric anticancer agent
-
M. Yokoyama, S. Inoue, K. Kataoka, N. Yui, and Y. Sakurai Preparation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. A new type of polymeric anticancer agent Die Makromol. Chem., Rapid Commun. 8 1987 431 435
-
(1987)
Die Makromol. Chem., Rapid Commun.
, vol.8
, pp. 431-435
-
-
Yokoyama, M.1
Inoue, S.2
Kataoka, K.3
Yui, N.4
Sakurai, Y.5
-
74
-
-
0025874282
-
Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood
-
M. Yokoyama, T. Okano, Y. Sakurai, H. Ekimoto, C. Shibazaki, and K. Kataoka Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood Cancer Res. 51 1991 3229 3236
-
(1991)
Cancer Res.
, vol.51
, pp. 3229-3236
-
-
Yokoyama, M.1
Okano, T.2
Sakurai, Y.3
Ekimoto, H.4
Shibazaki, C.5
Kataoka, K.6
-
75
-
-
0028346185
-
Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates
-
G. Kwon, S. Suwa, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates J. Control. Release 29 1994 17 23
-
(1994)
J. Control. Release
, vol.29
, pp. 17-23
-
-
Kwon, G.1
Suwa, S.2
Yokoyama, M.3
Okano, T.4
Sakurai, Y.5
Kataoka, K.6
-
76
-
-
0028135121
-
Improved synthesis of adriamycin-conjugated poly (ethylene oxide)-poly (aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin
-
M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Improved synthesis of adriamycin-conjugated poly (ethylene oxide)-poly (aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin J. Control. Release 32 1994 269 277
-
(1994)
J. Control. Release
, vol.32
, pp. 269-277
-
-
Yokoyama, M.1
Okano, T.2
Sakurai, Y.3
Kataoka, K.4
-
77
-
-
0032472352
-
Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor
-
M. Yokoyama, S. Fukushima, R. Uehara, K. Okamoto, K. Kataoka, Y. Sakurai, and T. Okano Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor J. Control. Release 50 1998 79 92
-
(1998)
J. Control. Release
, vol.50
, pp. 79-92
-
-
Yokoyama, M.1
Fukushima, S.2
Uehara, R.3
Okamoto, K.4
Kataoka, K.5
Sakurai, Y.6
Okano, T.7
-
78
-
-
0032846610
-
Roles of adriamycin and adriamycin dimer in antitumor activity of the polymeric micelle carrier system
-
S. Fukushima, M. Machida, T. Akutsu, K. Shimizu, S. Tanaka, K. Okamoto, H. Mashiba, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Roles of adriamycin and adriamycin dimer in antitumor activity of the polymeric micelle carrier system Colloids Surf., B 16 1999 227 236
-
(1999)
Colloids Surf., B
, vol.16
, pp. 227-236
-
-
Fukushima, S.1
MacHida, M.2
Akutsu, T.3
Shimizu, K.4
Tanaka, S.5
Okamoto, K.6
Mashiba, H.7
Yokoyama, M.8
Okano, T.9
Sakurai, Y.10
Kataoka, K.11
-
79
-
-
0036807955
-
Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil)
-
Y. Tsukioka, Y. Matsumura, T. Hamaguchi, H. Koike, F. Moriyasu, and T. Kakizoe Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil) Jpn. J. Cancer Res. 93 2002 1145 1153
-
(2002)
Jpn. J. Cancer Res.
, vol.93
, pp. 1145-1153
-
-
Tsukioka, Y.1
Matsumura, Y.2
Hamaguchi, T.3
Koike, H.4
Moriyasu, F.5
Kakizoe, T.6
-
80
-
-
33847256149
-
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors
-
Y. Fujisaka, A. Horiike, T. Shimizu, N. Yamamoto, Y. Yamada, and T. Tamura Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors Jpn. J. Clin. Oncol. 36 2006 768 774
-
(2006)
Jpn. J. Clin. Oncol.
, vol.36
, pp. 768-774
-
-
Fujisaka, Y.1
Horiike, A.2
Shimizu, T.3
Yamamoto, N.4
Yamada, Y.5
Tamura, T.6
-
81
-
-
41949089700
-
Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts
-
R. von Moos, B.J.K. Thuerlimann, M. Aapro, D. Rayson, K. Harrold, J. Sehouli, F. Scotte, D. Lorusso, R. Dummer, M.E. Lacouture, J. Lademann, and A. Hauschild Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts Eur. J. Cancer 44 2008 781 790
-
(2008)
Eur. J. Cancer
, vol.44
, pp. 781-790
-
-
Von Moos, R.1
Thuerlimann, B.J.K.2
Aapro, M.3
Rayson, D.4
Harrold, K.5
Sehouli, J.6
Scotte, F.7
Lorusso, D.8
Dummer, R.9
Lacouture, M.E.10
Lademann, J.11
Hauschild, A.12
-
82
-
-
0029904510
-
Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: In vivo evaluation of anti-cancer activity
-
E.V. Batrakova, T.Y. Dorodnych, E.Y. Klinskii, E.N. Kliushnenkova, O.B. Shemchukova, O.N. Goncharova, S.A. Arjakov, V.Y. Alakhov, and A.V. Kabanov Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity Br. J. Cancer 74 1996 1545 1552
-
(1996)
Br. J. Cancer
, vol.74
, pp. 1545-1552
-
-
Batrakova, E.V.1
Dorodnych, T.Y.2
Klinskii, E.Y.3
Kliushnenkova, E.N.4
Shemchukova, O.B.5
Goncharova, O.N.6
Arjakov, S.A.7
Alakhov, V.Y.8
Kabanov, A.V.9
-
83
-
-
33646473367
-
A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus
-
M.H. Kulke, B. Wu, J.W. Clark, P.C. Enzinger, T.J. Lynch, M. Vincitore, A. Michelini, and C.S. Fuchs A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus Cancer Invest. 24 2006 229 234
-
(2006)
Cancer Invest.
, vol.24
, pp. 229-234
-
-
Kulke, M.H.1
Wu, B.2
Clark, J.W.3
Enzinger, P.C.4
Lynch, T.J.5
Vincitore, M.6
Michelini, A.7
Fuchs, C.S.8
-
84
-
-
79955622641
-
Nanomedicine for oral chemotherapy
-
S.S. Feng, L. Zhao, and J. Tang Nanomedicine for oral chemotherapy Nanomedicine 6 2011 407 410
-
(2011)
Nanomedicine
, vol.6
, pp. 407-410
-
-
Feng, S.S.1
Zhao, L.2
Tang, J.3
-
85
-
-
33846671748
-
New-concept chemotherapy by nanoparticles of biodegradable polymers: Where are we now?
-
S.S. Feng New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now? Nanomedicine 1 2006 297 309
-
(2006)
Nanomedicine
, vol.1
, pp. 297-309
-
-
Feng, S.S.1
-
86
-
-
79951769859
-
The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery
-
H.J. Yao, R.J. Ju, X.X. Wang, Y. Zhang, R.J. Li, Y. Yu, L. Zhang, and W.L. Lu The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery Biomaterials 32 2011 3285 3302
-
(2011)
Biomaterials
, vol.32
, pp. 3285-3302
-
-
Yao, H.J.1
Ju, R.J.2
Wang, X.X.3
Zhang, Y.4
Li, R.J.5
Yu, Y.6
Zhang, L.7
Lu, W.L.8
-
87
-
-
34249914746
-
Passive diffusion of polymeric surfactants across lipid bilayers
-
F. Mathot, A. Schanck, F. Van Bambeke, A. Ariën, M. Noppe, M. Brewster, and V. Préat Passive diffusion of polymeric surfactants across lipid bilayers J. Control. Release 120 2007 79 87
-
(2007)
J. Control. Release
, vol.120
, pp. 79-87
-
-
Mathot, F.1
Schanck, A.2
Van Bambeke, F.3
Ariën, A.4
Noppe, M.5
Brewster, M.6
Préat, V.7
-
88
-
-
33344463203
-
Intestinal uptake and biodistribution of novel polymeric micelles after oral administration
-
F. Mathot, L. van Beijsterveldt, V. Préat, M. Brewster, and A. Ariën Intestinal uptake and biodistribution of novel polymeric micelles after oral administration J. Control. Release 111 2006 47 55
-
(2006)
J. Control. Release
, vol.111
, pp. 47-55
-
-
Mathot, F.1
Van Beijsterveldt, L.2
Préat, V.3
Brewster, M.4
Ariën, A.5
-
89
-
-
36148935211
-
Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier
-
F. Mathot, A. des Rieux, A. Ariën, Y.J. Schneider, M. Brewster, and V. Préat Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier J. Control. Release 124 2007 134 143
-
(2007)
J. Control. Release
, vol.124
, pp. 134-143
-
-
Mathot, F.1
Des Rieux, A.2
Ariën, A.3
Schneider, Y.J.4
Brewster, M.5
Préat, V.6
-
90
-
-
57349157027
-
The influence of bile acids on the oral bioavailability of vitamin K encapsulated in polymeric micelles
-
P.M. van Hasselt, G.E.P.J. Janssens, T.K. Slot, M. van der Ham, T.C. Minderhoud, M. Talelli, L.M. Akkermans, C.J.F. Rijcken, and C.F. van Nostrum The influence of bile acids on the oral bioavailability of vitamin K encapsulated in polymeric micelles J. Control. Release 133 2009 161 168
-
(2009)
J. Control. Release
, vol.133
, pp. 161-168
-
-
Van Hasselt, P.M.1
Janssens, G.E.P.J.2
Slot, T.K.3
Van Der Ham, M.4
Minderhoud, T.C.5
Talelli, M.6
Akkermans, L.M.7
Rijcken, C.J.F.8
Van Nostrum, C.F.9
-
91
-
-
46749107462
-
In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy
-
Z. Zhang, S.H. Lee, C.W. Gan, and S.S. Feng In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy Pharm. Res. 25 2008 1925 1935
-
(2008)
Pharm. Res.
, vol.25
, pp. 1925-1935
-
-
Zhang, Z.1
Lee, S.H.2
Gan, C.W.3
Feng, S.S.4
-
92
-
-
0032714228
-
Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS)
-
J.M. Dintaman, and J.A. Silverman Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharm. Res. 16 1999 1550 1556
-
(1999)
Pharm. Res.
, vol.16
, pp. 1550-1556
-
-
Dintaman, J.M.1
Silverman, J.A.2
-
93
-
-
0036849724
-
Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers
-
J. Zastre, J. Jackson, M. Bajwa, R. Liggins, F. Iqbal, and H. Burt Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by caco-2 cells using low molecular weight methoxypolyethylene glycol-block- polycaprolactone diblock copolymers Eur. J. Pharm. Biopharm. 54 2002 299 309
-
(2002)
Eur. J. Pharm. Biopharm.
, vol.54
, pp. 299-309
-
-
Zastre, J.1
Jackson, J.2
Bajwa, M.3
Liggins, R.4
Iqbal, F.5
Burt, H.6
-
94
-
-
33646367645
-
Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: Some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux
-
R.D. Dabholkar, R.M. Sawant, D.A. Mongayt, P.V. Devarajan, and V.P. Torchilin Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: Some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux Int. J. Pharm. 315 2006 148 157
-
(2006)
Int. J. Pharm.
, vol.315
, pp. 148-157
-
-
Dabholkar, R.D.1
Sawant, R.M.2
Mongayt, D.A.3
Devarajan, P.V.4
Torchilin, V.P.5
-
95
-
-
79956094659
-
Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles
-
L. Xiao, X. Xiong, X. Sun, Y. Zhu, H. Yang, H. Chen, L. Gan, H. Xu, and X. Yang Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles Biomaterials 32 2011 5148 5157
-
(2011)
Biomaterials
, vol.32
, pp. 5148-5157
-
-
Xiao, L.1
Xiong, X.2
Sun, X.3
Zhu, Y.4
Yang, H.5
Chen, H.6
Gan, L.7
Xu, H.8
Yang, X.9
-
96
-
-
79955522520
-
The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles
-
R. Mo, X. Jin, N. Li, C. Ju, M. Sun, C. Zhang, and Q. Ping The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles Biomaterials 32 2011 4609 4620
-
(2011)
Biomaterials
, vol.32
, pp. 4609-4620
-
-
Mo, R.1
Jin, X.2
Li, N.3
Ju, C.4
Sun, M.5
Zhang, C.6
Ping, Q.7
-
97
-
-
77951538902
-
Combining HME & solubilization: Soluplus - The solid solution
-
H. Hardung, D. Djuric, and S. Ali Combining HME & solubilization: Soluplus - the solid solution Drug Deliv. Technol. 10 2010 20 27
-
(2010)
Drug Deliv. Technol.
, vol.10
, pp. 20-27
-
-
Hardung, H.1
Djuric, D.2
Ali, S.3
-
99
-
-
84945509838
-
Hard to swallow
-
Hard to swallow Nature 448 2007 105 106
-
(2007)
Nature
, vol.448
, pp. 105-106
-
-
-
100
-
-
42449161986
-
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia
-
L. Wang, G.B. Zhou, P. Liu, J.H. Song, Y. Liang, X.J. Yan, F. Xu, B.S. Wang, J.H. Mao, Z.X. Shen, S.J. Chen, and Z. Chen Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia Proc. Natl. Acad. Sci. U. S. A. 105 2008 4826 4831
-
(2008)
Proc. Natl. Acad. Sci. U. S. A.
, vol.105
, pp. 4826-4831
-
-
Wang, L.1
Zhou, G.B.2
Liu, P.3
Song, J.H.4
Liang, Y.5
Yan, X.J.6
Xu, F.7
Wang, B.S.8
Mao, J.H.9
Shen, Z.X.10
Chen, S.J.11
Chen, Z.12
-
101
-
-
77955898834
-
The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity
-
W. Lam, S. Bussom, F. Guan, Z. Jiang, W. Zhang, E.A. Gullen, S.H. Liu, and Y.C. Cheng The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity Sci. Transl. Med. 2 2010 45ra59
-
(2010)
Sci. Transl. Med.
, vol.2
-
-
Lam, W.1
Bussom, S.2
Guan, F.3
Jiang, Z.4
Zhang, W.5
Gullen, E.A.6
Liu, S.H.7
Cheng, Y.C.8
-
102
-
-
67651227161
-
Application of targeted drug delivery system in Chinese medicine
-
D.C. Li, X.K. Zhong, Z.P. Zeng, J.G. Jiang, L. Li, M.M. Zhao, X.Q. Yang, J. Chen, B.S. Zhang, Q.Z. Zhao, M.Y. Xie, H. Xiong, Z.Y. Deng, X.M. Zhang, S.Y. Xu, and Y.X. Gao Application of targeted drug delivery system in Chinese medicine J. Control. Release 138 2009 103 112
-
(2009)
J. Control. Release
, vol.138
, pp. 103-112
-
-
Li, D.C.1
Zhong, X.K.2
Zeng, Z.P.3
Jiang, J.G.4
Li, L.5
Zhao, M.M.6
Yang, X.Q.7
Chen, J.8
Zhang, B.S.9
Zhao, Q.Z.10
Xie, M.Y.11
Xiong, H.12
Deng, Z.Y.13
Zhang, X.M.14
Xu, S.Y.15
Gao, Y.X.16
-
103
-
-
60749108001
-
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
-
H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
-
(2009)
Eur. J. Pharm. Biopharm.
, vol.71
, pp. 409-419
-
-
Maeda, H.1
Bharate, G.Y.2
Daruwalla, J.3
-
104
-
-
77952575335
-
Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects
-
H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 2010 797 802
-
(2010)
Bioconjug. Chem.
, vol.21
, pp. 797-802
-
-
Maeda, H.1
-
105
-
-
33847635618
-
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling
-
M.R. Kano, Y. Bae, C. Iwata, Y. Morishita, M. Yashiro, M. Oka, T. Fujii, A. Komuro, K. Kiyono, M. Kaminishi, K. Hirakawa, Y. Ouchi, N. Nishiyama, K. Kataoka, and K. Miyazono Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling Proc. Natl. Acad. Sci. U. S. A. 104 2007 3460 3465
-
(2007)
Proc. Natl. Acad. Sci. U. S. A.
, vol.104
, pp. 3460-3465
-
-
Kano, M.R.1
Bae, Y.2
Iwata, C.3
Morishita, Y.4
Yashiro, M.5
Oka, M.6
Fujii, T.7
Komuro, A.8
Kiyono, K.9
Kaminishi, M.10
Hirakawa, K.11
Ouchi, Y.12
Nishiyama, N.13
Kataoka, K.14
Miyazono, K.15
-
106
-
-
0037732561
-
Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium
-
S. Tanaka, T. Akaike, J. Wu, J. Fang, T. Sawa, M. Ogawa, T. Beppu, and H. Maeda Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium J. Drug Target. 11 2003 45 52
-
(2003)
J. Drug Target.
, vol.11
, pp. 45-52
-
-
Tanaka, S.1
Akaike, T.2
Wu, J.3
Fang, J.4
Sawa, T.5
Ogawa, M.6
Beppu, T.7
Maeda, H.8
-
107
-
-
70649088695
-
Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application
-
T. Seki, J. Fang, and H. Maeda Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application Cancer Sci. 100 2009 2426 2430
-
(2009)
Cancer Sci.
, vol.100
, pp. 2426-2430
-
-
Seki, T.1
Fang, J.2
Maeda, H.3
-
108
-
-
35348906219
-
MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin
-
G.Y. Lee, K. Park, S.Y. Kim, and Y. Byun MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin Eur. J. Pharm. Biopharm. 67 2007 646 654
-
(2007)
Eur. J. Pharm. Biopharm.
, vol.67
, pp. 646-654
-
-
Lee, G.Y.1
Park, K.2
Kim, S.Y.3
Byun, Y.4
-
109
-
-
77954217160
-
Thromboxane A(2) increases endothelial permeability through upregulation of interleukin-8
-
S.R. Kim, S.K. Bae, H.J. Park, M.K. Kim, K. Kim, S.Y. Park, H.O. Jang, I. Yun, Y.J. Kim, M.A. Yoo, and M.K. Bae Thromboxane A(2) increases endothelial permeability through upregulation of interleukin-8 Biochem. Biophys. Res. Commun. 397 2010 413 419
-
(2010)
Biochem. Biophys. Res. Commun.
, vol.397
, pp. 413-419
-
-
Kim, S.R.1
Bae, S.K.2
Park, H.J.3
Kim, M.K.4
Kim, K.5
Park, S.Y.6
Jang, H.O.7
Yun, I.8
Kim, Y.J.9
Yoo, M.A.10
Bae, M.K.11
-
110
-
-
77952468065
-
Matrix-specific protein kinase A signaling regulates p21-activated kinase activation by flow in endothelial cells
-
S.D. Funk, A. Yurdagul Jr., J.M. Green, K.A. Jhaveri, M.A. Schwartz, and A.W. Orr Matrix-specific protein kinase A signaling regulates p21-activated kinase activation by flow in endothelial cells Circ. Res. 106 2010 1394 1403
-
(2010)
Circ. Res.
, vol.106
, pp. 1394-1403
-
-
Funk, S.D.1
Yurdagul, Jr.A.2
Green, J.M.3
Jhaveri, K.A.4
Schwartz, M.A.5
Orr, A.W.6
-
111
-
-
33750324646
-
Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes
-
T. Ishida, M. Ichihara, X. Wang, and H. Kiwada Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes J. Control. Release 115 2006 243 250
-
(2006)
J. Control. Release
, vol.115
, pp. 243-250
-
-
Ishida, T.1
Ichihara, M.2
Wang, X.3
Kiwada, H.4
-
112
-
-
40849138014
-
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes
-
T. Ishida, and H. Kiwada Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes Int. J. Pharm. 354 2008 56 62
-
(2008)
Int. J. Pharm.
, vol.354
, pp. 56-62
-
-
Ishida, T.1
Kiwada, H.2
-
113
-
-
34248589255
-
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
-
X. Wang, T. Ishida, and H. Kiwada Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes J. Control. Release 119 2007 236 244
-
(2007)
J. Control. Release
, vol.119
, pp. 236-244
-
-
Wang, X.1
Ishida, T.2
Kiwada, H.3
-
114
-
-
77955415384
-
Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead
-
S.M. Moghimi, A.J. Andersen, S.H. Hashemi, B. Lettiero, D. Ahmadvand, A.C. Hunter, T.L. Andresen, I. Hamad, and J. Szebeni Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead J. Control. Release 146 2010 175 181
-
(2010)
J. Control. Release
, vol.146
, pp. 175-181
-
-
Moghimi, S.M.1
Andersen, A.J.2
Hashemi, S.H.3
Lettiero, B.4
Ahmadvand, D.5
Hunter, A.C.6
Andresen, T.L.7
Hamad, I.8
Szebeni, J.9
-
115
-
-
77951086240
-
Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes
-
H. Xu, K.Q. Wang, Y.H. Deng, and W. Chen da Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes Biomaterials 31 2010 4757 4763
-
(2010)
Biomaterials
, vol.31
, pp. 4757-4763
-
-
Xu, H.1
Wang, K.Q.2
Deng, Y.H.3
Chen Da, W.4
-
116
-
-
50249101054
-
Particle size-dependent triggering of accelerated blood clearance phenomenon
-
H. Koide, T. Asai, K. Hatanaka, T. Urakami, T. Ishii, E. Kenjo, M. Nishihara, M. Yokoyama, T. Ishida, H. Kiwada, and N. Oku Particle size-dependent triggering of accelerated blood clearance phenomenon Int. J. Pharm. 362 2008 197 200
-
(2008)
Int. J. Pharm.
, vol.362
, pp. 197-200
-
-
Koide, H.1
Asai, T.2
Hatanaka, K.3
Urakami, T.4
Ishii, T.5
Kenjo, E.6
Nishihara, M.7
Yokoyama, M.8
Ishida, T.9
Kiwada, H.10
Oku, N.11
-
117
-
-
69949132111
-
Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles
-
T. Ishihara, M. Takeda, H. Sakamoto, A. Kimoto, C. Kobayashi, N. Takasaki, K. Yuki, K. Tanaka, M. Takenaga, R. Igarashi, T. Maeda, N. Yamakawa, Y. Okamoto, M. Otsuka, T. Ishida, H. Kiwada, Y. Mizushima, and T. Mizushima Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles Pharm. Res. 26 2009 2270 2279
-
(2009)
Pharm. Res.
, vol.26
, pp. 2270-2279
-
-
Ishihara, T.1
Takeda, M.2
Sakamoto, H.3
Kimoto, A.4
Kobayashi, C.5
Takasaki, N.6
Yuki, K.7
Tanaka, K.8
Takenaga, M.9
Igarashi, R.10
Maeda, T.11
Yamakawa, N.12
Okamoto, Y.13
Otsuka, M.14
Ishida, T.15
Kiwada, H.16
Mizushima, Y.17
Mizushima, T.18
-
118
-
-
18144423485
-
Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats
-
X.Y. Wang, T. Ishida, M. Ichihara, and H. Kiwada Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats J. Control. Release 104 2005 91 102
-
(2005)
J. Control. Release
, vol.104
, pp. 91-102
-
-
Wang, X.Y.1
Ishida, T.2
Ichihara, M.3
Kiwada, H.4
-
119
-
-
77949272712
-
Accelerated blood clearance was not induced for a gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle in mice
-
H. Ma, K. Shiraishi, T. Minowa, K. Kawano, M. Yokoyama, Y. Hattori, and Y. Maitani Accelerated blood clearance was not induced for a gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle in mice Pharm. Res. 27 2010 296 302
-
(2010)
Pharm. Res.
, vol.27
, pp. 296-302
-
-
Ma, H.1
Shiraishi, K.2
Minowa, T.3
Kawano, K.4
Yokoyama, M.5
Hattori, Y.6
Maitani, Y.7
-
120
-
-
38049019767
-
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
-
A. Gabizon, R. Isacson, O. Rosengarten, D. Tzemach, H. Shmeeda, and R. Sapir An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin Cancer Chemother. Pharmacol. 61 2008 695 702
-
(2008)
Cancer Chemother. Pharmacol.
, vol.61
, pp. 695-702
-
-
Gabizon, A.1
Isacson, R.2
Rosengarten, O.3
Tzemach, D.4
Shmeeda, H.5
Sapir, R.6
|